Is Liraglutide approved/legal?

Yes. Liraglutide is an FDA-approved prescription medicine: Victoza for type 2 diabetes (2010) and Saxenda for chronic weight management (2014), and it is approved in many other jurisdictions. It is a prescription drug, not a supplement; 'research-use-only' gray-market sourcing is not approved for human use and carries quality and legal risks.

What is liraglutide's half-life and how often is it dosed?

Its half-life is roughly 13 hours, so it is injected subcutaneously once daily - unlike weekly semaglutide or tirzepatide. Daily dosing reflects its shorter, albumin-binding-driven half-life.

How does liraglutide differ from semaglutide?

Both are GLP-1 receptor agonists; liraglutide (~97% homology to native GLP-1) is dosed once daily with a half-life of roughly 13 hours, whereas semaglutide is once weekly (~1-week half-life). In head-to-head trials semaglutide generally produced greater HbA1c and weight reductions, though individual responses vary.

What are the main side effects?

Most commonly gastrointestinal (nausea, vomiting, diarrhea, constipation), especially during dose escalation. Less common but serious risks include pancreatitis and gallbladder disease; there is a boxed warning for rodent thyroid C-cell tumors, and it is contraindicated in people with a history of medullary thyroid carcinoma or MEN 2. Slow titration reduces side effects.

Is community/Reddit dosing reliable?

No. Community protocols from forums like r/liraglutide are anecdotal and provided here as research reference only, not medical advice. They vary widely, use unverified material, and lack the supervision and quality control of clinical trials. Liraglutide should be used only under qualified medical guidance.

Metabolic

Liraglutide

Also known as: Saxenda, Victoza, NN2211

GLP-1 receptor agonist with strong human-trial evidence for type 2 diabetes glycemic control, weight management, and cardiovascular risk reduction; dosed once daily.

Last updated July 18, 2026

Reconstitute this peptide Buy Liraglutide

Overview

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist sharing roughly 97% amino acid homology with native human GLP-1. It was the earlier, once-daily predecessor to weekly agents like semaglutide, marketed by Novo Nordisk as Victoza (type 2 diabetes) and Saxenda (chronic weight management). It is among the best-evidenced GLP-1 drugs, supported by the LEAD phase 3 program, the SCALE obesity trials, and the LEADER cardiovascular outcomes trial. A structural modification - an amino acid substitution (Arg34Lys) and acylation with a C16 palmitic fatty-acid chain via a glutamic-acid spacer - promotes reversible albumin binding and self-association (heptamer formation) at the injection site, slowing absorption and protecting against DPP-4 degradation. This extends the half-life to roughly 13 hours, enough for once-daily subcutaneous dosing but markedly shorter than semaglutide's ~1-week half-life, so it requires daily injection. In type 2 diabetes (Victoza, up to 1.8 mg/day) it improves glycemic control and, in LEADER, reduced major adverse cardiovascular events. At the higher 3.0 mg/day dose (Saxenda) it produces clinically meaningful weight loss, though generally less than once-weekly semaglutide 2.4 mg or tirzepatide in head-to-head data. It is a prescription medicine; as a YMYL medication it should only be used under qualified medical supervision, and gray-market 'research' supply carries purity, dosing, and safety risks. Nothing here is medical advice.

How it works

Liraglutide selectively activates the GLP-1 receptor, mimicking the incretin hormone GLP-1. It enhances glucose-dependent insulin secretion, suppresses glucagon (low intrinsic hypoglycemia risk), slows gastric emptying, and acts on appetite-regulating centers in the hypothalamus and hindbrain to increase satiety and reduce food intake. Unlike native GLP-1, which is degraded within minutes by DPP-4, its fatty-acid acylation drives albumin binding and self-association that slow absorption and enzymatic breakdown, giving a half-life of roughly 13 hours. Its shorter duration of action relative to weekly agents reflects pharmacokinetics rather than a different receptor target.

Researched effects

Clinical Improved glycemic control (HbA1c reduction of roughly 1.0-1.5%) in type 2 diabetes across the LEAD program
Clinical Reduced major adverse cardiovascular events in type 2 diabetes with high CV risk (MACE 13.0% vs 14.9%, HR 0.87 in LEADER)
Clinical Reduced cardiovascular and all-cause mortality in the high-risk LEADER population
Clinical Clinically meaningful weight loss at 3.0 mg/day (mean ~8% vs ~2.6% placebo at 56 weeks in SCALE Obesity and Prediabetes)
Clinical Reduced progression from prediabetes to type 2 diabetes (SCALE)
Anecdotal Appetite suppression and reduced food cravings reported anecdotally

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

For type 2 diabetes (Victoza), dosing typically starts at 0.6 mg subcutaneously once daily for at least one week (a non-therapeutic initiation dose that improves gastrointestinal tolerability), then increases to 1.2 mg/day; it may be increased to a maximum of 1.8 mg/day if further glycemic control is needed. For chronic weight management (Saxenda), a stepwise escalation is used: 0.6, 1.2, 1.8, 2.4, then 3.0 mg once daily, increasing by 0.6 mg at weekly intervals to reach the 3.0 mg/day maintenance dose; slow titration limits gastrointestinal side effects. Pediatric approvals also exist (Victoza in children aged 10 and older with type 2 diabetes; Saxenda in adolescents 12-17 with obesity). Dosing should be individualized and supervised by a qualified clinician.

Community-reported dosing (anecdotal)

Anecdotal and research-reference-only; NOT medical advice or instruction. Online communities (e.g., Reddit r/liraglutide, r/Saxenda, r/Peptides) and vendor reconstitution guides commonly describe following the labeled daily titration (0.6 mg start, weekly 0.6 mg steps toward 1.8-3.0 mg) to limit gastrointestinal side effects, reconstituting lyophilized material with bacteriostatic water and measuring doses with insulin syringes. Because liraglutide is dosed once daily rather than weekly, community protocols emphasize consistent daily timing. Some users report 'microdosing' below the labeled starting doses to minimize nausea. These self-directed protocols are unverified, vary widely, lack quality control, and can be dangerous; they are reported here only to document community behavior, not as an endorsement.

Half-life: ~13 hours
Routes: subcutaneous

Safety & side effects

The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and dyspepsia, usually mild-to-moderate and most pronounced during dose escalation. More serious but less common risks include acute pancreatitis, gallbladder disease (cholelithiasis/cholecystitis), and acute kidney injury from volume depletion (dehydration due to gastrointestinal losses). Modest increases in heart rate can occur. Hypoglycemia risk rises when combined with insulin or sulfonylureas. Liraglutide carries a boxed warning for thyroid C-cell tumors seen in rodents; human relevance is unknown, and it is contraindicated in those with a personal/family history of medullary thyroid carcinoma or MEN 2. Not recommended in pregnancy. Use only under medical supervision; gray-market product carries purity and dosing-accuracy risks.

Research summary

Liraglutide has one of the more mature clinical evidence bases among GLP-1 receptor agonists. The LEAD phase 3 program established its glycemic efficacy in type 2 diabetes, the SCALE program (including SCALE Obesity and Prediabetes, Pi-Sunyer et al., NEJM 2015) demonstrated clinically meaningful weight loss at 3.0 mg/day (mean ~8% vs ~2.6% placebo over 56 weeks), and LEADER (Marso et al., NEJM 2016) was among the first cardiovascular outcomes trials to show that a GLP-1 receptor agonist reduced major adverse cardiovascular events (13.0% vs 14.9%, HR 0.87) plus reductions in cardiovascular and all-cause mortality in high-risk type 2 diabetes. Mechanistically it is well characterized: a fatty-acylated GLP-1 analog whose albumin binding and self-association yield a half-life of roughly 13 hours supporting once-daily dosing. In head-to-head data it generally produces less weight loss and HbA1c reduction than once-weekly semaglutide (SUSTAIN-10; STEP-8) and the dual agonist tirzepatide, reflecting its older, shorter-acting profile; daily dosing is a practical trade-off. The safety profile is well understood: predominantly gastrointestinal tolerability issues mitigated by slow titration, with rarer concerns around pancreatitis and gallbladder disease and a precautionary thyroid C-cell contraindication based on rodent data (MTC/MEN 2). Community/anecdotal use exists but should be clearly separated from this clinical evidence; self-sourced 'research' material lacks the quality control and supervision under which the trial data were generated. Nothing here is medical advice.

FAQ

Is Liraglutide approved/legal?: Yes. Liraglutide is an FDA-approved prescription medicine: Victoza for type 2 diabetes (2010) and Saxenda for chronic weight management (2014), and it is approved in many other jurisdictions. It is a prescription drug, not a supplement; 'research-use-only' gray-market sourcing is not approved for human use and carries quality and legal risks.
What is liraglutide's half-life and how often is it dosed?: Its half-life is roughly 13 hours, so it is injected subcutaneously once daily - unlike weekly semaglutide or tirzepatide. Daily dosing reflects its shorter, albumin-binding-driven half-life.
How does liraglutide differ from semaglutide?: Both are GLP-1 receptor agonists; liraglutide (~97% homology to native GLP-1) is dosed once daily with a half-life of roughly 13 hours, whereas semaglutide is once weekly (~1-week half-life). In head-to-head trials semaglutide generally produced greater HbA1c and weight reductions, though individual responses vary.
What are the main side effects?: Most commonly gastrointestinal (nausea, vomiting, diarrhea, constipation), especially during dose escalation. Less common but serious risks include pancreatitis and gallbladder disease; there is a boxed warning for rodent thyroid C-cell tumors, and it is contraindicated in people with a history of medullary thyroid carcinoma or MEN 2. Slow titration reduces side effects.
Is community/Reddit dosing reliable?: No. Community protocols from forums like r/liraglutide are anecdotal and provided here as research reference only, not medical advice. They vary widely, use unverified material, and lack the supervision and quality control of clinical trials. Liraglutide should be used only under qualified medical guidance.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.